The Protease Cruzain Mediates Immune Evasion
Trypanosoma cruzi is the causative agent of Chagas' disease. Novel chemotherapy with the drug K11777 targets the major cysteine protease cruzain and disrupts amastigote intracellular development. Nevertheless, the biological role of the protease in infection and pathogenesis remains unclear as cruzain gene knockout failed due to genetic redundancy. A role for the T. cruzi cysteine protease cruzain in immune evasion was elucidated in a comparative study of parental wild type- and cruzain-deficient parasites. Wild type T. cruzi did not activate host macrophages during early infection (<60 min) and no increase in ∼P iκB was detected. The signaling factor NF-κB P65 colocalized with cruzain on the cell surface of intracellular wild type parasites, and was proteolytically cleaved. No significant IL-12 expression occurred in macrophages infected with wild type T. cruzi and treated with LPS and BFA, confirming impairment of macrophage activation pathways. In contrast, cruzain-deficient parasites induced macrophage activation, detectable iκB phosphorylation, and nuclear NF-κB P65 localization. These parasites were unable to develop intracellularly and survive within macrophages. IL 12 expression levels in macrophages infected with cruzain-deficient T. cruzi were comparable to LPS activated controls. Thus cruzain hinders macrophage activation during the early (<60 min) stages of infection, by interruption of the NF-κB P65 mediated signaling pathway. These early events allow T. cruzi survival and replication, and may lead to the spread of infection in acute Chagas' disease.
Vyšlo v časopise:
The Protease Cruzain Mediates Immune Evasion. PLoS Pathog 7(9): e32767. doi:10.1371/journal.ppat.1002139
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002139
Souhrn
Trypanosoma cruzi is the causative agent of Chagas' disease. Novel chemotherapy with the drug K11777 targets the major cysteine protease cruzain and disrupts amastigote intracellular development. Nevertheless, the biological role of the protease in infection and pathogenesis remains unclear as cruzain gene knockout failed due to genetic redundancy. A role for the T. cruzi cysteine protease cruzain in immune evasion was elucidated in a comparative study of parental wild type- and cruzain-deficient parasites. Wild type T. cruzi did not activate host macrophages during early infection (<60 min) and no increase in ∼P iκB was detected. The signaling factor NF-κB P65 colocalized with cruzain on the cell surface of intracellular wild type parasites, and was proteolytically cleaved. No significant IL-12 expression occurred in macrophages infected with wild type T. cruzi and treated with LPS and BFA, confirming impairment of macrophage activation pathways. In contrast, cruzain-deficient parasites induced macrophage activation, detectable iκB phosphorylation, and nuclear NF-κB P65 localization. These parasites were unable to develop intracellularly and survive within macrophages. IL 12 expression levels in macrophages infected with cruzain-deficient T. cruzi were comparable to LPS activated controls. Thus cruzain hinders macrophage activation during the early (<60 min) stages of infection, by interruption of the NF-κB P65 mediated signaling pathway. These early events allow T. cruzi survival and replication, and may lead to the spread of infection in acute Chagas' disease.
Zdroje
1. UrbinaJA 2010 Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115 55 68
2. BucknerFSNavabiN 2010 Advances in Chagas disease drug development: 2009-2010. Curr Opinion Infect Dis 23 609 616
3. McKerrowJHDoylePSEngelJCPodustLMRobertsonSA 2009 Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 104 263 269
4. ChagasC 1982 Coletanea de Trabalhos Cientificos 1909-1913. Editora Universidade de Brasilia 237 335
5. SchusterJPSchaubGA 2000 Trypanosoma cruzi: skin-penetration kinetics of vector derived metacyclic trypomastigotes. Int J Parasitol 30 1475 1479
6. GiordanengoLGuinazuNStempinCFretesRCerbanFM 2002 Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite. Eur J Immunol 32 1003 1011
7. StempinCSTanosTBCosoOACerbánFM 2003 Arginase induction promotes Trypanosoma cruzi intracellular replication in Cruzipain-treated J774 cells through the activation of multiple signaling pathways. Eur J Immunol 34 200 209
8. TomasAMKellyJM 1994 Transformation as an approach to functional analysis of the major cysteine protease of Trypanosoma cruzi. Biochem Soc Trans 22 90S
9. TomasAMKellyJM 1996 Stage-regulated expression of cruzipain, the major cysteine protease of Trypanosoma cruzi is independent of the level of RNA. Mol Biochem Parasitol 76 91 103
10. TomasAMMilesMAKellyJM 1997 Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. Eur J Biochem 244 596 603
11. YongVSchmitzVVannier-SantosMAde LimaAPLalmanachG 2000 Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases. Mol Biochem Parasitol 109 47 59
12. Lima A PAdos ReisCGFServeauCLalmanachGJulianoL 2001 Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors. Mol Biochem Parasitol 114 41 52
13. LimaAPAlmeidaPCTersariolLLSchmitzVSchmaierAH 2002 Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain. J Biol Chem 277 5875 5881
14. ScharfsteinJSchmitzVMorandiVCapellaMMLimaAP 2000 Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J Exp Med 192 1289 1300
15. AokiMPCanoRCPellegriniAVTanosTGuinazuNL 2006 Different signaling pathways are involved in cardiomyocyte survival induced by a Trypanosoma cruzi glycoprotein. Microbes Infect 8 1723 1731
16. EakinAEMillsAAHarthGMcKerrowJHCraikCS 1992 The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J Biol Chem 267 7411 7420
17. CazzuloJJ 1999 Cruzipain, major cysteine proteinase of Trypanosoma cruzi: sequence and genomic organization of the codifying genes. Medicina (B Aires) 59 7 10
18. EngelJCDoylePSHsiehIMcKerrowJH 1998 Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 188 725 734
19. DuschakVGCiaccioMNassertJRBasombrioMA 2001 Enzymatic activity, protein expression, and gene sequence of cruzipain in virulent and attenuated Trypanosoma cruzi strains. J Parasitol 87 1016 1022
20. DuschakVGRiarteASeguraELLaucellaSA 2001 Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas' disease. Immunol Letters 78 135 142
21. PaivaCNSouto-PadronTCostaDAGattassCR 1998 High expression of a functional cruzipain by a non-infective and non-pathogenic Trypanosoma cruzi clone. Parasitology 117 483 940
22. EngelJCTorres GarciaCHsiehIDoylePSMcKerrowJH 2000 Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi. J Cell Science 113 1345 1354
23. EngelJCDoylePSDvorakJA 1985 Trypanosoma cruzi: Biological characterization of clones derived from chronic chagasic patients. II. Quantitative analysis of the intracellular cycle. J Protozool 32 80 83
24. EngelJCDoylePSPalmerJHsiehIBaintonDF 1998 Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 111 597 606
25. EngelJCde CazzuloBMFStoppaniOAMCanattaJJBCazzuloJJ 1987 Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes. Mol Bioch Parasitol 26 1 10
26. DoylePSDvorakJAEngelJC 1984 Trypanosoma cruzi: Quantification and analysis of the infectivity of cloned stocks. J Protozool 31 280 283
27. BogyoMVerhelstSBellingard-DubouchaudVTobaSGreenbaumDC 2000 Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol 7 27 38
28. GreenbaumDCMedzihradszkyKFBurlingameABogyoM 2000 Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 7 569 581
29. HirschfeldMMaYWeisJHVogelSNWeisJJ 2000 Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165 618 622
30. TurerEETavaresRMMortierEHitotsumatsuOAdvinculaR 2008 Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 205 451 464
31. HitotsumatsuOAhmadRETavaresRMWangMPhilpottD 2008 The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28 381 390
32. TavaresRMTurerEELiuCLAdvinculaRScapiniP 2010 The Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival and Prevents Autoimmunity. Immunity 33 181 191
33. QuinonesMAhujaSKMelbyPCPateLReddickRL 2000 Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. Exp Med 192 507 515
34. CorralizaIMCampoMLSolerGModollelM 1994 Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 174 231 235
35. CameronPMcGachyAAndersonMPaulACoombsGH 2004 Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. J Immunol 173 3297 3304
36. GhoshS 1999 Regulation of inducible gene expression by the transcription factor NF-κB. Immunol Res 19 183 189
37. HallBSTamWSenRPereiraME 2000 Cell-specific activator of nuclear factor kappa B by the parasite Trypanosoma cruzi promotes resistance to intracellular infection. Mol Biol Cell 11 153 160
38. HaydenMSWestAPGhoshS 2006 NF-κB and the immune response. Oncogene 25 6758 6780
39. ChenYValleeSWuJVuDSondekJ 2004 Inhibition of NF-κB activity by IκBb in association with κB-ras. Mol Cell Biol 24 3048 3056
40. DiDonatoJAMercurioFKarinM 1995 Phosphorylation of iκBá precedes but is not sufficient for its dissociation from NF-κB. Mol Cell Biol 15 1302 1311
41. MarienfeldRFPalkowitschLGhoshS 2006 Dimerization of the iκB kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-κB activity. Mol Cell Biol 26 9209 9219
42. De PlaenIHanXBLiuXHsuehWGhoshS 2006 Lipopolysaccharide induces CXCL2/macrophage inflammatory protein-2 gene expression in enterocytes via NF-κB activation: independence from endogenous TNF-α and platelet activation factor. Immunology 118 153 163
43. PetersenCAKrumholzKABurleighBA 2005 Toll-like receptor 2 modulates IL-1B dependent cardiomyocyte hypertrophy triggered by Trypanosoma cruzi. Inf Immun 73 6974 6980
44. PetersenCAKrimholzKACarmenJSinaiAPBurleighBA 2006 Trypanosoma cruzi infection and nuclear factor kappa B activation prevent apoptosis in cardiac cells. Inf Imm 74 1580 1587
45. BaXShivali GuptaSDavidsonMGargNJ 2010 Trypanosoma cruzi Induces the Reactive Oxygen Species-PARP-1-RelA Pathway for Up-regulation of Cytokine Expression in Cardiomyocytes. J Biol Chem 285 11596 11606
46. HuangHCalderonTMBermanJWBraunsteinVLWeissLM 1999 Infection of Endothelial Cells with Trypanosoma cruzi Activates NF-κB and Induces Vascular Adhesion Molecule Expression. Infect Immun. 67 5434 5440
47. WuCGoshS 2003 Differential phosphorylation of the signal-responsive domain of iκBα and iκBβ by IκB kinases. J Biol Chem 34 31980 31987
48. BaeuerlePABaltimoreD 1996 NF-κB ten years after. Cell 87 113 120
49. IsraelAKroemerG 2006 NF-κB in life/death decisions: and introduction. Cell Death Differ 13 685 686
50. PerkinsNDGilmoreTD 2006 Good cop, bad cop: the different faces of NF-κB. Cell Death Differ 13 759 772
51. LiouHCHsiaCY 2003 Distinctions between c-Rel and other NF-κB proteins in immunity and disease. Bioassays 25 767 780
52. NelsonDEIhekwabaAECElliotMJohnsonJRGibneyCA 2004 Oscillations in NF-κB signaling control the dynamics of gene expression. Science 306 704 708
53. NascimentoAEde SouzaW 1996 High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Biol Cell 86 53 58
54. BurleighBAAndrewsNW 1995 The mechanisms of Trypanosoma cruzi invasion of mammalian cells. Ann Rev Microbiol 49 175 200
55. BurleighBA 2005 Host cell signaling and Trypanosoma cruzi invasion: do all roads lead to lysosomes? Sci STKE 293 36 43
56. LeyVAndrewsNWRobbinsESNussenzweigV 1998 Amastigotes of Trypanosoma cruzi sustain an infective cycle in mammalian cells. J Exp Med 168 649 659
57. KimaPEBurleighBAAndrewsNW 2000 Surface-targeted lysosomal membrane glyocoprotein-1 (Lamp-1) enhances lysosome exocytosis and cell invasion by Trypanosoma cruzi. Cell Microbiol 2 477 486
58. GaurURobertsSCDalviRPCorralizaIUllmanB 2007 An Effect of Parasite-Encoded Arginase on the Outcome of Murine Cutaneous Leishmaniasis. J Immunol 179 8446 8453
59. CamposMACloselMValenteEPCardosoJEAkiraS 2004 Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol 172 1711 1718
60. GordonS 2003 Alternative activation of macrophages. Nature Rev Immunol 3 23 35
61. NoëlWRaesGGhassabehGHDe BaetselierPBeschinA 2004 Alternatively activated macrophages during parasite infections. Tr Parasitol 20 126 133
62. ZhangSKimCCBatraSMcKerrowJHLokeP 2010 Delineation of diverse macrophage activation programs in response to intracellular parasites and cytokines. PLoS Negl Trop Dis 4 e648
63. GradoniLAscenziP 2004 Nitric oxide and anti-protozoon chemotherapy. Parasitol 46 101 103
64. ZhangLTarletonRL 1999 Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 180 480 486
65. TarletonR 2001 Parasite persistence in the etiology of Chagas’ disease. Int J Parasitol 31 549 553
66. GazzinelliRTRopertCCamposMA 2004 Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Imm Rev 201 9 14
67. TarletonRLGrusbyMJZhangL 2000 Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol 165 1520 1525
68. ReedSG 1998 In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol 140 4342 4347
69. KumarSTarletonRL 2001 Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol 166 4596 4603
70. BergeronMOlivierM 2006 Trypanosoma cruzi-Mediated IFN-Inducible Nitric Oxide Output in Macrophages Is Regulated by iNOS mRNA Stability. J Immunol 177 6271 80
71. HuangHPetkovaSBCohenAWBouzahzahBChanJ 2003 Activation of transcription factors AP-1 and NF-κB in murine chagasic myocarditis. Inf Immun 71 2859 2867
72. BaficaASantiagoHCGoldszmidRRopertCGazzinelliRT 2006 Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 177 3513 3519
73. RopertCCloselMChavesACLGazzinelliRT 2003 Inhibition of a p38/Stress-Activated Protein Kinase-2-Dependent Phosphatase Restores Function of IL-1 Receptor-Associated Kinase-1 and Reverses Toll-Like Receptor 2- and 4-Dependent Tolerance of Macrophages. J Immunol 171 1456 1465
74. Vaena de AvalosSBladerIJFisherMBoothroydJCBurleighBA 2002 Immediate early response to Trypanosoma cruzi infection involves minimal modulation of host cell transcription. J Biol Chem 277 639 644
75. BurleighBA 2004 Probing Trypanosoma cruzi biology with DNA microarrays. Parasitol 128 3 10
76. HeusslerVTRottenbergDSSchwabRKüenziPFernandezPC 2002 Hijacking of Host Cell IκK Signalosomes by the Transforming Parasite Theileria. Science 298 1033 1036
77. NesnanovNChumakivKMNeznanovaLAlmasanABanerjeeAK 2005 Proteolytic cleavage of the P65-RelA subunit of NF-κB during poliovirus infection. J Biol Chem 280 24153 24158
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 9
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
Najčítanejšie v tomto čísle
- Hostile Takeover by : Reorganization of Parasite and Host Cell Membranes during Liver Stage Egress
- HTLV-1 Propels Thymic Human T Cell Development in “Human Immune System” Rag2 gamma c Mice
- Exploiting and Subverting Tor Signaling in the Pathogenesis of Fungi, Parasites, and Viruses
- A Viral Ubiquitin Ligase Has Substrate Preferential SUMO Targeted Ubiquitin Ligase Activity that Counteracts Intrinsic Antiviral Defence